Compare BUSE & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BUSE | ANIP |
|---|---|---|
| Founded | 1868 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 1996 | 1999 |
| Metric | BUSE | ANIP |
|---|---|---|
| Price | $27.05 | $81.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $27.17 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 467.1K | 325.9K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | 0.52 | ★ 1.28 |
| Revenue | ★ $719,584,000.00 | $206,547,000.00 |
| Revenue This Year | $23.84 | $21.01 |
| Revenue Next Year | $3.82 | $17.59 |
| P/E Ratio | ★ $52.01 | $64.04 |
| Revenue Growth | ★ 55.66 | 2.47 |
| 52 Week Low | $21.63 | $57.34 |
| 52 Week High | $27.65 | $99.50 |
| Indicator | BUSE | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 59.87 | 54.47 |
| Support Level | $25.69 | $77.32 |
| Resistance Level | $27.11 | $83.58 |
| Average True Range (ATR) | 0.47 | 3.10 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 93.85 | 47.85 |
First Busey Corporation is a financial holding company whose subsidiaries provide retail and commercial banking services, remittance processing, and offer financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech, and Wealth Management. The banking segment generates a vast majority of its revenue.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.